179x Filetype DOC File size 0.18 MB Source: www.asperbio.com
ASPER ONCOGENETICS SAMPLE SUBMISSION FORM ORDERING PERSON AND REPORTING ADDITIONAL REPORTING INFORMATION INFORMATION (if applicable) Name (first name, last name) Institution Address E-mail Phone Results delivery by e-mail by regular mail Sample receipt Person confirmation E-mail BILLING INFORMATION By submitting DNA samples to Asper Biogene the client agrees that invoices shall be paid within 10 calendar days as of the invoice date and in case of delay in the payment, the open invoice amounts will accrue interest amounting to 0,1 % per calendar day. Contact person Institution Address E-mail Phone VAT account number In EU countries please add paying institution's VAT account number, otherwise 20% of VAT tax will be added to the invoice. PO number Invoice delivery by e-mail by regular mail Patient’s data needed for yes no invoicing SAMPLE INFORMATION Type whole blood in EDTA DNA Other...................................... Date of collection Fetal sample (for prenatal testing) Maternal sample (for prenatal testing) Date of collection Type DNA from CVS DNA from DNA whole blood in amniocentesis EDTA Method and/or kit of DNA extraction PATIENT INFORMATION Name Date of birth Sex Ethnic origin Clinical diagnosis Asper Biogene LLC • Vaksali 17A, 50410 Tartu, Estonia • phone +372 7307 295 • info@asperbio.com • www.asperbio.com 1 version 08/09/2021 ASPER ONCOGENETICS TESTS NGS panel of genes with CNV Sequencing of BRCA1, BRCA2 genes Breast and Ovarian Cancer Del/dup analysis of BRCA1, BRCA2, CHEK2 genes by MLPA Sequencing + del/dup analysis of BRCA1, BRCA2 genes by MLPA Cancer Predisposition NGS panel of genes with CNV Sequencing of APC gene Familial Adenomatous Polyposis Del/dup analysis of APC gene by MLPA NGS panel of genes with CNV Fanconi Anemia Del/dup analysis of FANCA, FANCB, FANCD2, PALB2 genes by MLPA NGS panel of genes with CNV Microsatellite instability Sequencing of MLH1 gene Lynch Syndrome Sequencing of MSH2 gene Sequencing of MSH6 gene Del/dup analysis of MLH1, MSH2 genes by MLPA Del/dup analysis of MSH6 gene by MLPA NGS panel of genes with CNV Melanoma Del/dup analysis of CDK4, CDKN2A, CDKN2B, MITF genes by MLPA Sequencing of MUTYH gene MUTYH-Associated Polyposis Targeted mutation analysis Del/dup analysis of GREM1, MUTYH, SCG5 genes by MLPA Sequencing of NBN gene Nijmegen Breakage Syndrome Targeted mutation analysis NGS panel of genes with CNV Polyposis Syndromes Del/dup analysis of BMPR1A, PTEN, SMAD4, STK11 genes by MLPA Prostate Cancer NGS panel of genes with CNV Renal Cancer NGS panel of genes with CNV Asper Biogene LLC • Vaksali 17A, 50410 Tartu, Estonia • phone +372 7307 295 • info@asperbio.com • www.asperbio.com 2 version 08/09/2021 ASPER ONCOGENETICS TESTS NGS panel of genes with CNV Thyroid Cancer Del/dup analysis of MEN1, SDHB, SDHC, SDHD genes by MLPA Von Hippel-Lindau Disease Sequencing of VHL gene CUSTOM TEST NGS panel of genes with CNV Del/dup analysis by MLPA Del/dup analysis of selected regions by Chromosomal Microarray Analysis Single gene sequencing Single mutation analysis PATIENT’S CLINICAL INFORMATION Reason for referral confirmation of clinical diagnosis testing of at-risk family members cancer predisposition assessment risk assessment for adverse drug reactions Age at the onset of symptoms…………............................. Patient´s clinical features no symptoms cancer, location.............................................................................................................................................................. Previous genetic testing not done results: ....................................................................................................................................................................................... ....................................................................................................................................................................................... Family history unknown diagnosis…………………………………………………………………………………………………………........................ specify the relation to the proband and age at diagnosis…………………………………………………………………..... ....................................................................................................................................................................................... Authorization to use remaining sample material and test results Asper Biogene may use de-identified (without personal identifying information) remaining sample material and test re- sults for quality improvements and/or scientific purposes. I give my consent to use my de-identified sample material and test results as described above I do not give my consent to use my de-identified sample material and test results as described above Name of patient……………………………………………………………………………………………………………………… Patient’s signature…………………………………………………………………………………………………………………… Date…………………………………………………………………………………………………………………………………… Asper Biogene LLC • Vaksali 17A, 50410 Tartu, Estonia • phone +372 7307 295 • info@asperbio.com • www.asperbio.com 3 version 08/09/2021 Important: By sending samples and placing an order customer accepts Terms and Conditions and Privacy Policy of Asper Biogene (see website for details). Asper Biogene LLC • Vaksali 17A, 50410 Tartu, Estonia • phone +372 7307 295 • info@asperbio.com • www.asperbio.com 4 version 08/09/2021
no reviews yet
Please Login to review.